# Sensitisation to Conventional Therapies

The sensitisation story is where shikonin becomes more clinically interesting than as a standalone supplement concept.

Its main value is not that it adds one more stressor.

It is that it may re-open pathways that resistant tumour cells depend on.

### The two main sensitisation routes

#### PKM2 inhibition

Resistant tumour cells often rely heavily on altered glycolysis.

When shikonin inhibits PKM2, that metabolic support weakens.

This can make other treatments work again.

#### Necroptosis induction

If apoptosis is blocked, shikonin may still kill through necroptosis.

That means resistance at the caspase or Bcl-2 level does not necessarily protect the cell.

### Best-supported examples

#### Tamoxifen

In ER-positive breast-cancer cells, shikonin complements tamoxifen by degrading ERα while tamoxifen blocks receptor activation.

#### Cisplatin

In bladder-cancer models, shikonin re-sensitises resistant cells by PKM2 inhibition and necroptotic escape from blocked apoptosis.

#### Doxorubicin

Breast-cancer data suggests complementary stress that may reduce the dose needed for a given cytotoxic effect.

#### Gefitinib-related derivatives

Some shikonin derivatives re-sensitise resistant NSCLC models through EGFR-degradation-linked mechanisms.

### What this means in practice

Readers should treat sensitisation data as a scientific signal, not a self-experiment instruction.

Resistance reversal in a cell line is not the same thing as safe co-treatment in a patient.

### Bottom line

Shikonin's most serious oncology value may be as a resistance-pressure compound rather than as a monotherapy candidate.

That is the right place to watch the literature next.

### Key references

Zhang L et al. (2020). Shikonin and 4-hydroxytamoxifen — ER+ breast cancer sensitisation.\
<https://www.springermedizin.de/shikonin-and-4-hydroxytamoxifen-synergistically-inhibit-the-prol/17786520>

Li Z et al. (2018). Cisplatin sensitisation in bladder cancer via PKM2 inhibition and necroptosis. *PMC.*\
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6231221/>

Ahmad F et al. (2024). Doxorubicin sensitisation findings. *Journal of Pharmacy and Pharmacology.*\
<https://academic.oup.com/jpp/article/76/8/967/7656703>

Yang J et al. (2019). EGFR/gefitinib resistance reversal — NSCLC context. *European Journal of Pharmacology.*\
<https://www.sciencedirect.com/science/article/abs/pii/S0014299919306193>

{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}

{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}


---

# Agent Instructions: Querying This Documentation

If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter:

```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/sensitisation-to-conventional-therapies.md?ask=<question>
```

The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.